NRX Pharmaceuticals (NRXP) Receivables (2020 - 2026)

NRX Pharmaceuticals (NRXP) has reported Receivables for 6 consecutive years, with $412000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables changed N/A year-over-year to $412000.0 in Q2 2026; TTM through Jun 2026 was $412000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $314000.0, changed N/A from the prior year.
• Receivables was $412000.0 for Q2 2026 at NRX Pharmaceuticals, up from $362000.0 in the prior quarter.
• Over five years, Receivables peaked at $3.4 million in Q3 2025 and troughed at $6000.0 in Q1 2023.
• A 5-year average of $483000.0 and a median of $141000.0 in 2022 frame the typical range for Receivables.
• Across the five-year window, Receivables plunged 95.56% in 2023 and changed 0.0% in 2024, its largest moves.
• Over 5 years, Receivables stood at $270000.0 in 2022, then sank by 95.56% to $12000.0 in 2023, then slumped by 50.0% to $6000.0 in 2024, then jumped by 5133.33% to $314000.0 in 2025, then surged by 31.21% to $412000.0 in 2026.
• The last three Receivables figures came in at $412000.0 (Q2 2026), $362000.0 (Q1 2026), and $314000.0 (Q4 2025), per Business Quant data.